Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 54474
Gene Symbol: KRT20
KRT20
0.100 Biomarker disease BEFREE Following a broad panel of immunohistochemical stains, the strong positive staining of the spindle cells for LCA (CD45), CD20, and Bcl-6 confirmed the diagnosis of follicle center cell lymphoma. 31693188 2020
Entrez Id: 54474
Gene Symbol: KRT20
KRT20
0.100 Biomarker disease BEFREE Both patients were diagnosed with NMOSD and initiated on anti-CD20 agents prior to lymphoma diagnosis, though the short duration of exposure argues against a direct role. 31706113 2020
Entrez Id: 54474
Gene Symbol: KRT20
KRT20
0.100 Biomarker disease BEFREE Rituximab is an anti-CD20 antibody used to deplete B lymphocytes in lymphoma and autoimmune disease. 29561469 2018
Entrez Id: 54474
Gene Symbol: KRT20
KRT20
0.100 Biomarker disease BEFREE Bispecific antibody (CD20-CD47SL) fusion of anti-CD20 (Rituximab) and anti-CD47 also demonstrated a synergistic effect against lymphoma in preclinical models. 29709247 2018
Entrez Id: 54474
Gene Symbol: KRT20
KRT20
0.100 AlteredExpression disease BEFREE Here, we report the production of an anti-cancer monoclonal antibody against the CD20 protein from egg whites of transgenic hens, and validated the bio-functional activity of the protein in B-lymphoma and B-lymphoblast cells. 29554481 2018
Entrez Id: 54474
Gene Symbol: KRT20
KRT20
0.100 Biomarker disease BEFREE Amplification of CD20 Cross-Linking in Rituximab-Resistant B-Lymphoma Cells Enhances Apoptosis Induction by Drug-Free Macromolecular Therapeutics. 29595951 2018
Entrez Id: 54474
Gene Symbol: KRT20
KRT20
0.100 Biomarker disease BEFREE We investigated combination therapy of IL-15 with rituximab in a syngeneic mouse model of lymphoma transfected with human CD20 and with alemtuzumab (Campath-1H) in a xenograft model of human adult T cell leukemia (ATL). 30373815 2018
Entrez Id: 54474
Gene Symbol: KRT20
KRT20
0.100 Biomarker disease BEFREE CD20-positive T-cell lymphoma is a very rare type of lymphoma that is refractory to CHOP-like regimens alone. 29561444 2018
Entrez Id: 54474
Gene Symbol: KRT20
KRT20
0.100 Biomarker disease BEFREE A phase I study of recombinant human (rh) IL-18 given with ofatumumab was undertaken in patients with CD20 lymphoma who had undergone high-dose chemotherapy and autologous peripheral blood stem cell transplantation. 29517616 2018
Entrez Id: 54474
Gene Symbol: KRT20
KRT20
0.100 AlteredExpression disease BEFREE Age and CD20 Expression Are Significant Prognostic Factors in Human Herpes Virus-8-negative Effusion-based Lymphoma. 30273194 2018
Entrez Id: 54474
Gene Symbol: KRT20
KRT20
0.100 Biomarker disease BEFREE In order to treat lymphoma, monoclonal antibodies (mAb) can target different antigens, including CD19, CD20 and CD22 on the surface of B-cells. 29922424 2018
Entrez Id: 54474
Gene Symbol: KRT20
KRT20
0.100 Biomarker disease BEFREE It is known for some time that the immune cell composition of the lymphoma microenvironment is important because high numbers of tissue-infiltrating macrophages correlate with poor outcome in patients receiving chemotherapy but not in patients receiving the combination of chemotherapy and CD20-specific monoclonal antibody rituximab. 29974035 2018
Entrez Id: 54474
Gene Symbol: KRT20
KRT20
0.100 Biomarker disease BEFREE Using immunohistochemistry, the lymphoma cells were positive for CD3 (weak), CD20 and HHV8. 29105119 2018
Entrez Id: 54474
Gene Symbol: KRT20
KRT20
0.100 Biomarker disease BEFREE We engineered antibody fragments targeting human CD20 and studied their potential as immunoPET tracers in transgenic mice (huCD20TM) and in a murine lymphoma model expressing human CD20.<b>Experimental Design:</b> Anti-CD20 cys-diabody (cDb) and cys-minibody (cMb) based on rituximab and obinutuzumab (GA101) were radioiodinated and used for immunoPET imaging of a murine lymphoma model. 28928164 2017
Entrez Id: 54474
Gene Symbol: KRT20
KRT20
0.100 Biomarker disease BEFREE TP53 mutations are independent predictors of survival in untreated patients with aggressive CD20+ lymphoma. 28614910 2017
Entrez Id: 54474
Gene Symbol: KRT20
KRT20
0.100 Biomarker disease BEFREE Using a syngeneic immunocompetent mouse model, we observed that targeting lymphoma with interferon-α (IFNα) abolished resistance of B-cell lymphoma to anti-CD20 while limiting interferon (IFN)-associated systemic toxicity in the host. 28533311 2017
Entrez Id: 54474
Gene Symbol: KRT20
KRT20
0.100 Biomarker disease BEFREE The cytotoxic effects of RDMs in combination with ultrasound (RDMs+US) were evaluated in vitro in CD20+ and CD20- cell lines, and its antitumor activities were assessed in Raji (CD20+) and Jurkat (CD20-) lymphoma cell-grafted mice. 27902473 2017
Entrez Id: 54474
Gene Symbol: KRT20
KRT20
0.100 Biomarker disease BEFREE The in vitro tests confirmed that targeted RDMSNs could selectively adhere to the surface of lymphoma B cells via specific binding with the CD20 antigen and be internalized into CD20 positive Raji cells but few CD20 negative Jurkat cells, which leads to increased cytotoxicity and apoptosis of the DOX in Raji cells due to the release of the entrapped DOX with high efficiency in the slightly acidic intracellular microenvironment. 28166836 2017
Entrez Id: 54474
Gene Symbol: KRT20
KRT20
0.100 Biomarker disease BEFREE Addition of rituximab to salvage therapy before ASCT appears to improve the response rate, transplantation rate, and overall survival in patients with CD20+ lymphoma who responded to R-CHOP. 27266754 2017
Entrez Id: 54474
Gene Symbol: KRT20
KRT20
0.100 Biomarker disease BEFREE Both STINGa and TLRa induced cytokine release, modulated FcγR expression, and augmented mAb-mediated tumor cell phagocytosis <i>in vitro</i> However, only STINGa reversed the suppressive FcγR profile <i>in vivo</i>, providing strong adjuvant effects to anti-CD20 mAb in murine models of lymphoma. 28512240 2017
Entrez Id: 54474
Gene Symbol: KRT20
KRT20
0.100 AlteredExpression disease BEFREE Genetically induced lymphoma Gal-1 expression ablated antibody-dependent lymphoma phagocytosis in vitro and lymphoma sensitivity to CD20 immunotherapy in vivo. 26888257 2016
Entrez Id: 54474
Gene Symbol: KRT20
KRT20
0.100 Biomarker disease BEFREE High avidity T-cell clones were identified that readily recognized and lysed primary HLA-A2pos B-cell leukemia and lymphoma in the absence of reactivity against CD20-negative but HLA-A2pos healthy hematopoietic and nonhematopoietic cells. 27776339 2016
Entrez Id: 54474
Gene Symbol: KRT20
KRT20
0.100 Biomarker disease BEFREE Our results, further supported by gene set enrichment analyses in a clinical data set of chronic lymphocytic leukemia patient samples exposed to a rituximab-containing treatment regimen, provide important mechanistic insights into the biologic complexity of anti-CD20-evoked tumor responses, and unveil cellular senescence as a hitherto unrecognized effector principle of the antibody component in lymphoma immunochemotherapy. 26880268 2016
Entrez Id: 54474
Gene Symbol: KRT20
KRT20
0.100 AlteredExpression disease BEFREE CD20CAR-T cells responded efficiently to CD20-downregulated lymphoma and leukemia targets, including rituximab- or ofatumumab-refractory primary chronic lymphocytic leukemia cells. 25520398 2015
Entrez Id: 54474
Gene Symbol: KRT20
KRT20
0.100 AlteredExpression disease BEFREE The patient was tentatively diagnosed with primary cutaneous CD30-negative large T-cell lymphoma with aberrant CD20 co-expression, pending workup to exclude systemic lymphoma with cutaneous involvement. 25942672 2015